Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.16697 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole.
Curr Med Res Opin
January 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU for patients, caregivers, and clinicians. Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval.
View Article and Find Full Text PDFTreating people who have experienced deep and prolonged developmental trauma, that is, complex post-traumatic stress disorder (cPTSD), can be challenging given the complexity and severity of their presentations. The main features of complex post-traumatic stress disorder, that is, affective and behavioral dysregulation, altered self-experience and identity disturbances, relational difficulties, negative self-concepts, and negative pathogenic beliefs, are, at the same time, therapeutic goals and obstacles to treatment. Therefore, clinicians must be aware of these difficulties in order to identify them and be ready to treat them when they arise during therapy with the same client.
View Article and Find Full Text PDFFirst relapse in older adults with multiple myeloma: Creating new pathways in uncharted territory.
Br J Haematol
January 2025
University of Nebraska Medical Center/Nebraska Medicine, Omaha, Nebraska, USA.
Treatment options for older adults with relapsed multiple myeloma are constrained by the toxicities of existing treatments, the ageing-associated vulnerabilities that may increase the risk of poor treatment tolerance and patient preferences for treatments that do not impair their function or cognition. The study by Toussea et al. epitomizes approaches to designing trials specifically for more vulnerable older adults and moves the field forward with a regimen of great interest for older adults experiencing their first relapse.
View Article and Find Full Text PDFEditorial: Way to Go with OSA Biomarkers.
Sleep
January 2025
Professor of Medicine and Physiology & Biophysics, University Hospitals, Cleveland Medical Center, Case Western University School of Medicine, Cleveland OH, USA.
Generative artificial intelligence in graduate medical education.
Front Med (Lausanne)
January 2025
Clinical Informatics Fellowship Program, Baylor Scott & White Health, Round Rock, TX, United States.
Generative artificial intelligence (GenAI) is rapidly transforming various sectors, including healthcare and education. This paper explores the potential opportunities and risks of GenAI in graduate medical education (GME). We review the existing literature and provide commentary on how GenAI could impact GME, including five key areas of opportunity: electronic health record (EHR) workload reduction, clinical simulation, individualized education, research and analytics support, and clinical decision support.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!